News Faron’s Clever-1 drug shows promise in blood cancers Faron Pharmaceuticals has reported data from a phase 1/2 trial pointing to the potential of its macrophage-directed antibody bexmarilimab as a treatment for blood cancers
Oncology Liver cancer diagnostic gets FDA breakthrough status, with P... Mursla Bio CEO and founder Pierre Arséne discusses the breakthrough designation from the FDA for their blood test to catch liver cancer early.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face